CD38 and Miyoshi myopathy: For example, in mouse models targeting the CD38 and PD-1 pathway in MM, lung cancer, and colon adenocarcinoma, the combination of a CD38 antibody and PD-1 antibody resulted in enhanced anti-tumor activity, when compared to targeting either pathway alone [60].